Content about H2 antagonist

March 26, 2012

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing.

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing. For the 12 weeks ended Jan. 12, sales of Tums were up more than 3%, and it still was among the top three antacids.


February 9, 2012

The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.

Patients should immediately contact their healthcare professional and seek care if they take PPIs and develop diarrhea that does not improve, the agency stated.

March 4, 2011

NEW YORK — Sure, the plethora of proton-pump inhibitors dotting digestive aisles these days have generated plenty of buzz among antacids, but what do heartburn sufferers do while they wait for the PPI to begin working? They turn to an immediate relief option like the Tums and Tums Ultra brands, which together generated growth of 96.3% to $24.9 million for the 12 weeks ended Jan. 23 across food, drug and mass (minus Walmart), according to SymphonyIRI Group data.